EUCTR2010-018405-12-LT进行中（未招募）不适用
Evaluation of the Long-Term Safety, Tolerability, and Pharmacokinetics of Cariprazine in Patients with Schizophrenia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written (signed or thumbprinted) informed consent obtained from the patient before the initiation of any study specific procedures
- •2. Written (signed or thumbprinted) informed consent obtained from the caregiver before the initiation of any study-specific procedures
- •3. Male or female inpatient, 18 to 60 years of age, inclusive
- •4. Current diagnosis of schizophrenia according to DSM-IV-TR criteria (295.30 Paranoid Type, 295.10 Disorganized Type, 295.20 Catatonic Type, or 295.90 Undifferentiated Type) as determined by the Structured Clinical Interview for DSM IV (new patients only)
- •5. Diagnosis of schizophrenia for a minimum of 1 year before Visit 1 (new patients only)
- •6. Completion of the double-blind treatment period in one of the lead-in studies (RGH MD-04 or RGH-MD-05) (except new patients)
- •7. PANSS positive syndrome subscale total score (PANSS items P1 to P7) = 25
- •8. CGI-S score = 3
- •9. Patients who are eligible to continue as outpatients in the opinion of the Principal Investigator
- •10. Negative serum ß-human chorionic gonadotropin (ß-hCG) pregnancy test (applies to female patients of childbearing potential only)
- •11. Normal physical examination findings, vital signs, clinical laboratory test results, and electrocardiogram (ECG) results or abnormal results that are judged not clinically significant by the PI and documented as such in the eCRF
- •12. Body mass index between 18 and 40 kg/m2, inclusive
- •13. A designated caregiver who will accompany the patient at each visit (If a caregiver cannot attend a visit, written documentation from the caregiver of the patient’s study medication compliance will need to be provided.)
- •14. Patients must be able to speak and understand the local language sufficiently to understand the nature of the study
- •15. Caregivers must be able to speak and understand the local language sufficiently to understand the nature of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Currently meeting DSM-IV-TR criteria for any of the following:
- •Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders
- •Bipolar I and II disorder
- •Pervasive developmental disorder, mental retardation, delirium, dementia, amnestic and other cognitive disorders
- •Known or suspected borderline or antisocial personality disorder or other DSM IV-TR axis II disorder of sufficient severity to interfere with participation in this study
- •Substance abuse or dependence (other than nicotine or caffeine) within the 3 months prior to Visit 1 of this study (new patients only)
- •2. Patients in their first episode of psychosis
- •3. Treatment-resistant schizophrenia over the last 2 years
- •4. Positive result from the blood alcohol test or from the urine drug screen (UDS) for any prohibited medication
- •5. History of intolerance or hypersensitivity to other drugs of the same class as cariprazine or to rescue medications, or any history of severe drug allergy or hypersensitivity
- •7. Suicide risk
- •8. Electroconvulsive therapy in the 3 months before Visit 1 of this study (new patients only)
- •9. Previous lack of response to electroconvulsive therapy
- •10. Treatment with a depot neuroleptic less than 1 cycle in duration before Visit 1 (new patients only)
- •11. Treatment with clozapine in the past 10 years (see protocol for exceptions)
- •12. Requiring concomitant treatment with any of the prohibited medications, supplements, or herbal products listed in protocol Appendix II (see protocol)
- •13. At Visit 2, requiring pharmacologic treatment for the control of EPS (new patients only)
- •14. Patients who have extrapyramidal symptoms that are not adequately controlled by anti-EPS medications in the opinion of the PI at Visit 1 (RGH-MD-04 or RGH-MD-05 completers only)
- •15. Patients who in the opinion of the PI, are experiencing ongoing, uncontrolled, clinically significant adverse events at Visit 1 (RGH-MD-04 or RGH-MD-05 completers only)
- •16. Prior participation in any investigational study of RGH-188 (cariprazine), except for patients who participated in RGH-MD-04 or RGH-MD-05
- •17. Women who meet the following criteria:
- •Pregnant, breastfeeding, and/or planning to become pregnant and/or breastfeed during the study
- •Not at least 2 years postmenopausal, surgically sterile, or practicing a reliable method of contraception that will continue for the duration of the study.
- •19. Any cardiovascular disease that is clinically significant, unstable, or decompensated. Other excluding conditions are detailed in the protocol.
- •20. Hypo- or hyperthyroidism, unless stabilized
- •21. Abnormally low level of vitamin B-12 or folate or psychiatric symptoms possibly secondary to any other organic medical condition
- •23. History of seizure disorder, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes the patient toward a risk for seizure
- •24. Known history of cataracts or presence of any of the following Lens Opacities Classification System III (LOCS III) findings at the screening examination:
- •Nuclear opalescence (LOCS III NO) > 4
- •Nuclear color (LOCS III NC) > 4
- •Cortical cataract (LOCS III C) > 3
- •Posterior subcapsular cataract (LOCS III P) > 0.5
- •25. Patients who meet any of the following LOCS III assessment criteria:
- •History of intraocular surgery or laser treatment
- •History or current findings of ocular disease (open- or narrow-angle glaucoma, retinopathies, corneal diseases)
- •Allergies to dilating drops,
研究者
相似试验
已完成
3 期
ong-term Study of Cariprazine in Patients with Schizophrenia.CTRI/2010/091/001400Forest Research Institute600
进行中（未招募）
1 期
Study to assess the long-term safety and tolerability of erenumab in migraine patientsMigraine prophylaxisMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-002201-22-DEovartis Pharma GmbH640
进行中（未招募）
1 期
Estudio de seguridad y tolerabilidad a largo plazo de la administración abierta Arikace en pacientes con fibrosis quística con infección crónica por Pseudomonas aeruginosaInfeccion pulmonar por Pseudomonas Aeruginosa/ colonizacion en pacientes con fibrosis quisticaMedDRA version: 14.0Level: PTClassification code 10011763Term: Cystic fibrosis lungSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000443-24-ESInsmed Incorporated250
招募中
1 期
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of PLN-74809Respiratory - Other respiratory disorders / diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonInflammatory and Immune System - Other inflammatory or immune system disordersPrimary Sclerosing CholangitisIdiopathic pulmonary fibrosisACTRN12620000536965Pliant Therapeutics, Inc.80
进行中（未招募）
1 期
ong Term Follow-up Study of AAVAnc80-hOTOF Gene TherapyOtoferlin gene-mediated hearing lossCTIS2024-512584-31-00Akouos Inc.14